Full Press Release Details
Innovative Concierge Service for Patients Participating in Its Clinical Studies
patient support and services; partners with BBK Worldwide
PARK, N.J., October 25, 2021 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical
company focused on the discovery and development of targeted drugs for the treatment of cancer, today announced it is collaborating with
BBK Worldwide to provide new concierge services for patients participating in its clinical studies. These services are designed to improve
patient's and their caregivers access to high quality care and innovative treatments for their cancer.
new concierge services program underscores our focus on patients and our commitment to providing them with best-in-class treatments and
support. Providing something as simple as securing transportation to clinics and lodging to assistance with reimbursement and study-related
expenses can have a major positive impact on patients during very difficult times," said James Caruso, president and CEO of Cellectar.
"We recognize the challenges facing patients and their families as they battle cancer and navigate the clinical study process and
are honored to support them through this journey. With iopofosine I-131 (iopofosine) in our ongoing pivotal study for Waldenstrom's
we have also initiated the development of our Patient Assistance Program which will be made available upon FDA approval."
BBK Worldwide's products and services reflect
their commitment to the patient experience. Their four business units include a concierge-supported engagement solution center, a creative
advertising agency, a consulting firm, and a technology company. The synergy between the units creates game-changing technologies and
services that have been the gold standard in the industry for more than 37 years. Their tools inspire study communities and alleviate
site administrative burdens, enabling doctors and nurses to spend more time with patients.
are thrilled to partner with Cellectar in support of patients that may benefit from treatment with iopofosine," said Rob
Laurens, principal and chief innovation officer of BBK Worldwide. "BBK is founded on the principle of putting the patient first,
and we share Cellectar's commitment to helping patients navigate the many challenges associated with cancer treatment."
is currently investigating iopofosine in a global, pivotal expansion cohort in Waldenstrom's macroglobulinemia (WM) patients
who have received at least two prior lines of therapy, including Bruton tyrosine kinase inhibitor failed or suboptimal response. The WM
cohort will enroll up to 50 patients to evaluate the efficacy and safety of iopofosine for marketing approval. The company is also evaluating
iopofosine in late line, hexa-drug refractory multiple myeloma patients in its Phase 2 CLOVER-1 study in hematologic malignancies. Iopofosine
is also in two Phase 1 studies, one in pediatric sarcomas, neuroendocrine tumors and solid tumors and an investigator-initiated study
evaluating the drug in head and neck cancer.
A full-service R&D marketing
firm housing an award-winning creative group, a high-end consultancy, a sophisticated technology entity, and an engagement solution center,
BBK Worldwide has maintained its position at the forefront of patient recruitment and engagement for more than 37 years. An industry game
changer, BBK's patented smart technology TrialCentralNet drives the company's innovation. Headquartered near
Boston, Massachusetts, BBK has partners and offices across Europe and the Asia-Pacific region.
About Cellectar Biosciences, Inc.
Cellectar Biosciences
is focused on the discovery and development of drugs for the treatment of cancer. The company is developing proprietary drugs independently
and through research and development collaborations. The company's core objective is to leverage its proprietary Phospholipid Drug
Conjugate (PDC) delivery platform to develop PDCs that specifically target cancer cells, delivering improved efficacy and better
safety as a result of fewer off-target effects. The company's PDC platform possesses the potential for the discovery and development
of the next-generation of cancer-targeting treatments, and it plans to develop PDCs independently and through research and development
The company's product
pipeline includes iopofosine, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), and proprietary
preclinical PDC chemotherapeutic programs and multiple partnered PDC assets.
more information, please visit www.cellectar.com and www.wmclinicaltrial.com or join the conversation by liking and
following us on the company's social media channels: Twitter, LinkedIn, and Facebook.
Forward-Looking Statement Disclaimer
This news release contains
forward-looking statements. You can identify these statements by our use of words such as "may," "expect," "believe,"
"anticipate," "intend," "could," "estimate," "continue," "plans," or their
negatives or cognates. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties
that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current
beliefs and expectations as to such future outcomes including our expectations of the impact of the COVID-19 pandemic. Drug discovery
and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties
related to the ability to raise additional capital, uncertainties related to the disruptions at our sole source supplier of iopofosine,
the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development
thereof, patient enrollment and the completion of clinical studies, the FDA review process and other government regulation, our ability
to maintain orphan drug designation in the United States for iopofosine, the volatile market for priority review vouchers, our pharmaceutical
collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product
pricing and third-party reimbursement. A complete description of risks and uncertainties related to our business is contained in our periodic
reports filed with the Securities and Exchange Commission including our Form 10-K for the year ended December 31, 2020. These forward-looking
statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements.